Regeneron Pharmaceuticals Inc

REGN

Equity

ISIN US75886F1075 / Valor 965755

NASDAQ (2024-11-20)

USD 743.35-0.17%

Regeneron Pharmaceuticals Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Regeneron Pharmaceuticals Inc. is a prominent biotechnology firm that specializes in the discovery, development, and commercialization of innovative medicines aimed at transforming the lives of patients suffering from serious diseases. Since its inception over three decades ago by a team of physician-scientists, the company has established a reputation for its consistent ability to convert scientific discoveries into a range of FDA-approved treatments, with a significant portion of its product portfolio being developed in-house. Regeneron focuses on addressing a variety of medical conditions, including eye diseases, allergic and inflammatory disorders, cancer, cardiovascular and metabolic issues, pain, hematologic conditions, infectious diseases, and rare diseases. The company is also known for its pioneering VelociSuite® technologies, notably VelocImmune®, which leverages genetically-engineered mice to produce fully-human antibodies, and its involvement in one of the world's most ambitious genetics sequencing projects through the Regeneron Genetics Center®. These efforts underscore Regeneron's commitment to enhancing and expediting the drug development process, positioning it as a leader in the biotechnology sector.

Summarized from source with an LLMView SourceSector: Technology

Revenue Growth

Regeneron Pharmaceuticals Inc. reported a 12% increase in total revenues for the second quarter of 2024, reaching $3.55 billion compared to $3.16 billion in the second quarter of 2023. This growth was driven by strong performances across several key products.

Dupixent Sales

Global net sales of Dupixent®, recorded by Sanofi, saw a significant increase of 27% in the second quarter of 2024, totaling $3.56 billion compared to the same period in 2023. This highlights the continued demand and market penetration of Dupixent.

EYLEA Sales

In the second quarter of 2024, U.S. net sales for EYLEA® HD and EYLEA® increased by 2% to $1.53 billion, including $304 million from EYLEA HD. This growth reflects the successful transition of patients to the newer EYLEA HD formulation.

Libtayo Sales

Regeneron Pharmaceuticals Inc. reported a 42% increase in global net sales of Libtayo® for the second quarter of 2024, reaching $297 million compared to the same quarter in 2023. This substantial growth underscores the expanding adoption of Libtayo in the market.

Earnings Per Share

For the second quarter of 2024, Regeneron Pharmaceuticals Inc. saw a 46% increase in GAAP diluted earnings per share (EPS), reaching $12.41. Non-GAAP diluted EPS also rose by 13% to $11.56, despite an unfavorable $0.18 impact from an acquired IPR&D charge.

Summarized from source with an LLMView Source

Key figures

-7.27%1Y

13.9%3Y

116%5Y

Performance

21.0%1Y

26.8%3Y

30.5%5Y

Volatility